Mitoxantrone, Etoposide, and Cytarabine (MEC) Plus Lenalidomide for Relapsed or Refractory Acute Myeloid Leukemia | Aplastic Anemia & MDS International Foundation
  1. Treatments
  2. Clinical Trials
  3. Mitoxantrone, Etoposide, and Cytarabine (MEC) Plus Lenalidomide for Relapsed or Refractory Acute Myeloid Leukemia
Mitoxantrone, Etoposide, and Cytarabine (MEC) Plus Lenalidomide for Relapsed or Refractory Acute Myeloid Leukemia

Clinical Trial: NCT03118466

For more details on this clinical trial, including contact information, please see this trial’s listing on clinicaltrials.gov:
https://clinicaltrials.gov/ct2/show/NCT03118466
Purpose: 

This research study is evaluating how a drug called lenalidomide, given in combination with the standard chemotherapy regimen of Mitoxantrone, Etoposide, and Cytarabine, commonly referred to as MEC, works in individuals with either relapsed or refractory AML

Status: 
Recruiting
Study Date: 
Tue, 04/18/2017 to Mon, 09/30/2024
Bone Marrow Disease(s): 
  • acute myeloid leukemia (AML)
Associated Drug(s): 
Lenalidomide
Intervention: 
Drug: Etoposide A Drug that interfere with the action of topoisomerase enzymes (topoisomerase I and II). Topoisomerase enzymes control the manipulation of the structure of DNA necessary for replication. Other Name: Toposar Drug: Cytarabine Cytarabine is an antimetabolite antineoplastic agent that inhibits the synthesis of DNA. Other Name: Depocyt Drug: Lenalidomide It may act by inhibiting the growth of new blood vessels (angiogenesis) in tumors, enhancing the status of the immune system, or decreasing cytokine and growth factor production Other Name: REVLIMID Drug: Mitoxantrone It interfere with cell reproduction Other Name: Novantrone